December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

63.54 +2.17 (+3.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? ↗
Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten. 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
News headline image
Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead ↗
A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments. 
Via Benzinga
News headline image
CYTK Earnings Jump 3,065% ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review. 
Via Benzinga
News headline image
Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
From DJS Law Group
Via Business Wire
News headline image
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? ↗
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
News headline image
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It ↗
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.